Overview

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Status:
Completed

Trial end date:
2021-05-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the efficacy and safety of long-term administration of the oral proteasome inhibitor ixazomib as part of ixazomib in combination with lenalidomide and dexamethasone (IRd) therapy in patients with relapsed and/or refractory multiple myeloma (RRMM) treated initially with an injectable proteasome inhibitor-based therapy.

Phase:

Phase 4

Details

Lead Sponsor:

Takeda

Treatments:

BB 1101
Bortezomib
Dexamethasone
Dexamethasone acetate
Glycine
Ixazomib
Lenalidomide
Proteasome Inhibitors
Thalidomide